Domain Therapeutics

Domain Therapeutics develops small molecules targeting G-coupled protein receptors.

Domain Therapeutics is a biopharmaceutical company located in Strasbourg, France, dedicated to the discovery and early development of small molecules targeting G-coupled Protein Receptors (GPCRs), one of the best classes of drug targets. Domain Therapeutics is using its innovative and proprietary technology platform DTect-Allâ„¢ to identify orthosteric and allosteric ligands of GPCRs, including the so called Silent Allosteric Modulators (SAMs) that represent a unique source of compounds that cannot be discovered by standard technologies. DTect-Allâ„¢ is able to address difficult GPCRs such as orphan and peptidic GPCRs.